City

Beijing (3)

Condition

Acute Myeloid Leukemia (2)

Relapsed/Refractory Acute Myeloid Leukemia (1)

Overall Status

Recruiting (3)

Phase

phase 2 (2)

phase 1 (1)

Sponsor

Chinese PLA General Hospital (3)

Collaborator

First Hospital of China Medical University (2)

People's Liberation Army (PLA) Strategic Support Force Characteristic Medical Center (2)

The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army (2)

The 960th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army (2)

The General Hospital of Northern Theater Command (2)

The General Hospital of Western Theater Command (2)

Yantai Yuhuangding Hospital (2)

Air Force Medical Center (1)

Air Force Military Medical University, China (1)

Intervention

azacytidine;cytarabine;aclacinomycin;chidamide;venetoclax;granulocyte colony-stimulating factor (2)

"3+7" (1)

azacytidine;cytarabine;aclamycin;chidamide;venetoclax;granulocyte (1)

best-available therapy(bat) regimen (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (3)

Study Type

Interventional (3)

CACAG

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Acute Myeloid Leukemia Trial in Beijing (Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte

Recruiting

Acute Myeloid Leukemia

Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
"3+7"

Beijing, Beijing, China

Chinese PLA General Hospital

Sep 29, 2023

Relapsed/Refractory Acute Myeloid Leukemia Trial in Beijing

Recruiting

Relapsed/Refractory Acute Myeloid Leukemia

Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
Best-Available Therapy(BAT) Regimen

Beijing, Beijing, China

Chinese PLA General Hospital

Oct 10, 2023

Acute Myeloid Leukemia Trial in Beijing (azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte)

Recruiting

Acute Myeloid Leukemia

azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte

Beijing, Beijing, China

Chinese PLA General Hospital

Dec 13, 2022